-- Tourmaline Oil (TOU.TO) 周三盘后公布，其第一季度利润增长，但商品销售收入和已实现收益同比下降。 这家加拿大西部天然气生产商第一季度盈利6.576亿美元，合每股1.69美元，高于去年同期的2.127亿美元，合每股0.56美元。FactSet此前预期每股盈利0.85美元。 商品销售收入和已实现收益从去年同期的18.9亿美元降至16.9亿美元。FactSet此前预期为16亿美元。 该季度平均日产量为666,089桶油当量，符合此前66万至67万桶油当量的预期范围。 公司预计2026年全年平均日产量为62万至64万桶油当量，“其中包括此前披露的和平河高地资产出售、阿尔伯塔深盆地乙烷开采合同到期以及2026年勘探开发资本预算削减1.75亿美元的影响。” 公司补充道，预计凝析油、丙烷和国际液化天然气价格上涨将使2026年和2027年全年自由现金流均达到约9亿美元。 根据声明，Tourmaline董事会计划于6月初宣布每股0.50美元的季度基本股息，该股息将于6月30日支付给6月15日营业结束时登记在册的股东。 该公司股票在多伦多证券交易所收盘下跌1.10美元，至66.85美元。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661